Latest news with #RolandGreen
Business Wire
13-05-2025
- Business
- Business Wire
Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies
MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of its T-Body™ trispecific antibody platform, a next-generation technology designed to reliably direct correct chain pairing and afford high expression and assembly efficiency in a variety of antibody constructs, including complex trispecific constructs. Building on the success of Invenra's B-Body ® bispecific platform, the T-Body platform expands the company's capabilities to address complex therapeutic targets with enhanced developability. "Trispecific antibodies represent a major leap forward in therapeutic design, and our T-Body platform offers a unique approach to unlock their potential," said Roland Green, Ph.D., CEO and Chairman of Invenra. "By integrating proprietary CH3 domains, streamlining purification, and achieving strong expression yields, we're empowering partners to rapidly discover and advance a new class of multispecific therapeutics." Designed for Versatility and Manufacturability The T-Body platform features an IgG-like architecture with proprietary CH3 domain pairs that substitute for traditional CH1/CL domains in two Fab arms. This configuration improves chain pairing, reduces mispairing, and supports efficient expression and assembly in mammalian cells. The design also enables 'Plug & Play' variable domain compatibility, allowing insertion of VH/VL pairs from diverse sources—including phage libraries, humanized mice, and AI-designed antibodies. Invenra's T-Body platform features include: Proprietary CH3 Design: Improves heavy/light chain pairing and overall assembly. Streamlined Purification: One-step purification with Protein A and anti-CH1 resin compatibility. Robust Expression: High yields in multiple transient expression systems. Flexible Targeting: Supports multivalent and/or multispecific formats with both kappa and lambda light chains. Manufacturing-Ready: Compatible with standard IgG production processes for rapid scale-up. Expanding the Future of Multispecific Antibodies With the T-Body platform, Invenra continues its mission to accelerate next-generation multispecific antibody discovery in areas such as oncology, autoimmune disease, and immunotherapy. The platform's modularity and developability profile position it for internal programs and strategic partnerships aimed at addressing complex biology through engineered multispecific formats. "This platform is a natural extension of our antibody engineering leadership," Green added. "We're excited to work with partners to move trispecific candidates from concept to clinic." Invenra is highlighting the T-Body platform at the 21st Annual PEGS Boston May 12-16, with details available at its poster (A051), booth (612), and online at About Invenra Inc. Invenra Inc. is a biotechnology company specializing in next-generation multispecific antibody discovery and development. Its proprietary B-Body ® platform enables the rapid generation of highly developable bispecifics and now supports both Rapid Bispecific Discovery Services—delivering lead panels in as little as four months—and B-Body Express™, which quickly produces high-quality bispecifics from partner-provided sequences. Invenra's newly launched T-Body™ platform expands these capabilities for efficient expression, correct chain pairing, and robust assembly of trispecific constructs. Invenra partners globally with pharmaceutical and biotech companies to accelerate therapeutic antibody programs from discovery through preclinical development.
Yahoo
13-05-2025
- Business
- Yahoo
Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies
MADISON, Wis., May 13, 2025--(BUSINESS WIRE)--Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of its T-Body™ trispecific antibody platform, a next-generation technology designed to reliably direct correct chain pairing and afford high expression and assembly efficiency in a variety of antibody constructs, including complex trispecific constructs. Building on the success of Invenra's B-Body® bispecific platform, the T-Body platform expands the company's capabilities to address complex therapeutic targets with enhanced developability. "Trispecific antibodies represent a major leap forward in therapeutic design, and our T-Body platform offers a unique approach to unlock their potential," said Roland Green, Ph.D., CEO and Chairman of Invenra. "By integrating proprietary CH3 domains, streamlining purification, and achieving strong expression yields, we're empowering partners to rapidly discover and advance a new class of multispecific therapeutics." Designed for Versatility and Manufacturability The T-Body platform features an IgG-like architecture with proprietary CH3 domain pairs that substitute for traditional CH1/CL domains in two Fab arms. This configuration improves chain pairing, reduces mispairing, and supports efficient expression and assembly in mammalian cells. The design also enables "Plug & Play" variable domain compatibility, allowing insertion of VH/VL pairs from diverse sources—including phage libraries, humanized mice, and AI-designed antibodies. Invenra's T-Body platform features include: Proprietary CH3 Design: Improves heavy/light chain pairing and overall assembly. Streamlined Purification: One-step purification with Protein A and anti-CH1 resin compatibility. Robust Expression: High yields in multiple transient expression systems. Flexible Targeting: Supports multivalent and/or multispecific formats with both kappa and lambda light chains. Manufacturing-Ready: Compatible with standard IgG production processes for rapid scale-up. Expanding the Future of Multispecific Antibodies With the T-Body platform, Invenra continues its mission to accelerate next-generation multispecific antibody discovery in areas such as oncology, autoimmune disease, and immunotherapy. The platform's modularity and developability profile position it for internal programs and strategic partnerships aimed at addressing complex biology through engineered multispecific formats. "This platform is a natural extension of our antibody engineering leadership," Green added. "We're excited to work with partners to move trispecific candidates from concept to clinic." Invenra is highlighting the T-Body platform at the 21st Annual PEGS Boston May 12-16, with details available at its poster (A051), booth (612), and online at About Invenra Inc. Invenra Inc. is a biotechnology company specializing in next-generation multispecific antibody discovery and development. Its proprietary B-Body® platform enables the rapid generation of highly developable bispecifics and now supports both Rapid Bispecific Discovery Services—delivering lead panels in as little as four months—and B-Body Express™, which quickly produces high-quality bispecifics from partner-provided sequences. Invenra's newly launched T-Body™ platform expands these capabilities for efficient expression, correct chain pairing, and robust assembly of trispecific constructs. Invenra partners globally with pharmaceutical and biotech companies to accelerate therapeutic antibody programs from discovery through preclinical development. View source version on Contacts Bryan Glaser, Vice President of Business Developmentbglaser@ 608-441-8319https:// Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies
MADISON, Wis., May 13, 2025--(BUSINESS WIRE)--Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of its T-Body™ trispecific antibody platform, a next-generation technology designed to reliably direct correct chain pairing and afford high expression and assembly efficiency in a variety of antibody constructs, including complex trispecific constructs. Building on the success of Invenra's B-Body® bispecific platform, the T-Body platform expands the company's capabilities to address complex therapeutic targets with enhanced developability. "Trispecific antibodies represent a major leap forward in therapeutic design, and our T-Body platform offers a unique approach to unlock their potential," said Roland Green, Ph.D., CEO and Chairman of Invenra. "By integrating proprietary CH3 domains, streamlining purification, and achieving strong expression yields, we're empowering partners to rapidly discover and advance a new class of multispecific therapeutics." Designed for Versatility and Manufacturability The T-Body platform features an IgG-like architecture with proprietary CH3 domain pairs that substitute for traditional CH1/CL domains in two Fab arms. This configuration improves chain pairing, reduces mispairing, and supports efficient expression and assembly in mammalian cells. The design also enables "Plug & Play" variable domain compatibility, allowing insertion of VH/VL pairs from diverse sources—including phage libraries, humanized mice, and AI-designed antibodies. Invenra's T-Body platform features include: Proprietary CH3 Design: Improves heavy/light chain pairing and overall assembly. Streamlined Purification: One-step purification with Protein A and anti-CH1 resin compatibility. Robust Expression: High yields in multiple transient expression systems. Flexible Targeting: Supports multivalent and/or multispecific formats with both kappa and lambda light chains. Manufacturing-Ready: Compatible with standard IgG production processes for rapid scale-up. Expanding the Future of Multispecific Antibodies With the T-Body platform, Invenra continues its mission to accelerate next-generation multispecific antibody discovery in areas such as oncology, autoimmune disease, and immunotherapy. The platform's modularity and developability profile position it for internal programs and strategic partnerships aimed at addressing complex biology through engineered multispecific formats. "This platform is a natural extension of our antibody engineering leadership," Green added. "We're excited to work with partners to move trispecific candidates from concept to clinic." Invenra is highlighting the T-Body platform at the 21st Annual PEGS Boston May 12-16, with details available at its poster (A051), booth (612), and online at About Invenra Inc. Invenra Inc. is a biotechnology company specializing in next-generation multispecific antibody discovery and development. Its proprietary B-Body® platform enables the rapid generation of highly developable bispecifics and now supports both Rapid Bispecific Discovery Services—delivering lead panels in as little as four months—and B-Body Express™, which quickly produces high-quality bispecifics from partner-provided sequences. Invenra's newly launched T-Body™ platform expands these capabilities for efficient expression, correct chain pairing, and robust assembly of trispecific constructs. Invenra partners globally with pharmaceutical and biotech companies to accelerate therapeutic antibody programs from discovery through preclinical development. View source version on Contacts Bryan Glaser, Vice President of Business Developmentbglaser@ 608-441-8319https:// Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-04-2025
- Business
- Business Wire
Service, Enabling Rapid Access to its Premier B-Body® Bispecific Antibody Platform
MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of its B-Body Express ™ Antibody Expression service. This new offering enables biotechnology and pharmaceutical companies to rapidly access Invenra's premier B-Body® bispecific antibody platform, delivering high-purity, validated bispecific antibodies derived from partner-provided antibody sequences. Designed to accelerate preclinical research, the service delivers speed without compromising yield, purity, or access to cutting-edge technology. B-Body Express ™ allows partners to leverage Invenra's proven B-Body® technology using their own antibody sequences, expressed in validated formats. The service initially focuses on the highly developable 1x1 B-Body® format, alongside traditional monoclonal antibodies (mAbs). Invenra also plans to expand the B-Body Express ™ service to include standardized 2x1 and 2x2 B-Body® formats in the near future. B-Body Express ™ - Validation Scale Service Features: Accelerated Production: High-purity B-Body® (1x1) and mAbs produced at flexible 50mL, 200mL, or 500mL scales. Rapid Turnaround: Delivery of fully QC-analyzed antibodies within weeks of final DNA vector validation. Full Yield Delivery: Partners receive the entire antibody yield produced, maximizing research utility. Upcoming Format Options: Standardized 2x1 and 2x2 B-Body® formats launching soon. Simple Licensing Path: Includes research-use rights with a clearly defined path to commercial terms. "Advancing bispecific programs requires both speed and access to platforms engineered for developability," said Dr. Roland Green, CEO at Invenra. "Our B-Body Express ™ service provides exactly that. Partners gain immediate access to our B-Body® platform for their 1x1 bispecifics and mAbs, with high-quality results delivered just 8 weeks after final DNA vector validation. We've structured this offering with a transparent research-use license and a straightforward path to commercial terms, supporting both immediate research and long-term development goals. The upcoming expansion to 2x1 and 2x2 formats will further enhance this capability." The B-Body® platform is engineered to overcome key challenges in bispecific antibody development and manufacturing. Its human IgG-like scaffold incorporates clinically validated Fc substitutions and proprietary Fab arm pairing technologies to ensure correct chain assembly, high heterodimer efficiency, and simplified CMC processes. B-Body® bispecific antibodies routinely achieve yields of 6–11 g/L, >95% purity after a single purification step, and exhibit excellent stability and viscosity profiles —ideal for subcutaneous administration and standard manufacturing workflows. Starting from validated partner sequences, B-Body Express ™ manages expression, purification, and quality control - delivering ready-to-use B-Body bispecific antibodies to accelerate early development. About Invenra Inc. Invenra Inc. pioneers the discovery and development of next-generation multispecific antibodies for unmet therapeutic needs. Its proprietary B-Body® platform enables the creation of highly developable bispecific and multispecific antibodies with superior yield, purity, and stability. Invenra collaborates with partners worldwide, providing cutting-edge antibody discovery solutions and expert services, including the new B-Body Express ™ service, to accelerate the journey of novel medicines to patients.
Yahoo
22-04-2025
- Business
- Yahoo
Invenra Launches B-Body Express™ Service, Enabling Rapid Access to its Premier B-Body® Bispecific Antibody Platform
MADISON, Wis., April 22, 2025--(BUSINESS WIRE)--Invenra Inc., a leader in multispecific antibody discovery and development, today announced the launch of its B-Body Express™ Antibody Expression service. This new offering enables biotechnology and pharmaceutical companies to rapidly access Invenra's premier B-Body® bispecific antibody platform, delivering high-purity, validated bispecific antibodies derived from partner-provided antibody sequences. Designed to accelerate preclinical research, the service delivers speed without compromising yield, purity, or access to cutting-edge technology. B-Body Express™ allows partners to leverage Invenra's proven B-Body® technology using their own antibody sequences, expressed in validated formats. The service initially focuses on the highly developable 1x1 B-Body® format, alongside traditional monoclonal antibodies (mAbs). Invenra also plans to expand the B-Body Express™ service to include standardized 2x1 and 2x2 B-Body® formats in the near future. B-Body Express™ - Validation Scale Service Features: Accelerated Production: High-purity B-Body® (1x1) and mAbs produced at flexible 50mL, 200mL, or 500mL scales. Rapid Turnaround: Delivery of fully QC-analyzed antibodies within weeks of final DNA vector validation. Full Yield Delivery: Partners receive the entire antibody yield produced, maximizing research utility. Upcoming Format Options: Standardized 2x1 and 2x2 B-Body® formats launching soon. Simple Licensing Path: Includes research-use rights with a clearly defined path to commercial terms. "Advancing bispecific programs requires both speed and access to platforms engineered for developability," said Dr. Roland Green, CEO at Invenra. "Our B-Body Express™ service provides exactly that. Partners gain immediate access to our B-Body® platform for their 1x1 bispecifics and mAbs, with high-quality results delivered just 8 weeks after final DNA vector validation. We've structured this offering with a transparent research-use license and a straightforward path to commercial terms, supporting both immediate research and long-term development goals. The upcoming expansion to 2x1 and 2x2 formats will further enhance this capability." The B-Body® platform is engineered to overcome key challenges in bispecific antibody development and manufacturing. Its human IgG-like scaffold incorporates clinically validated Fc substitutions and proprietary Fab arm pairing technologies to ensure correct chain assembly, high heterodimer efficiency, and simplified CMC processes. B-Body® bispecific antibodies routinely achieve yields of 6–11 g/L, >95% purity after a single purification step, and exhibit excellent stability and viscosity profiles—ideal for subcutaneous administration and standard manufacturing workflows. Starting from validated partner sequences, B-Body Express™ manages expression, purification, and quality control - delivering ready-to-use B-Body bispecific antibodies to accelerate early development. About Invenra Inc. Invenra Inc. pioneers the discovery and development of next-generation multispecific antibodies for unmet therapeutic needs. Its proprietary B-Body® platform enables the creation of highly developable bispecific and multispecific antibodies with superior yield, purity, and stability. Invenra collaborates with partners worldwide, providing cutting-edge antibody discovery solutions and expert services, including the new B-Body Express™ service, to accelerate the journey of novel medicines to patients. View source version on Contacts Bryan Glaser, Vice President of Business Developmentbglaser@ 608-441-8319https://
